JP2014523897A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523897A5
JP2014523897A5 JP2014517952A JP2014517952A JP2014523897A5 JP 2014523897 A5 JP2014523897 A5 JP 2014523897A5 JP 2014517952 A JP2014517952 A JP 2014517952A JP 2014517952 A JP2014517952 A JP 2014517952A JP 2014523897 A5 JP2014523897 A5 JP 2014523897A5
Authority
JP
Japan
Prior art keywords
phenyl
aminomethyl
ethoxy
ethyl
benzylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523897A (ja
JP5921679B2 (ja
Filing date
Publication date
Priority claimed from GB1111682.9A external-priority patent/GB2494851A/en
Application filed filed Critical
Publication of JP2014523897A publication Critical patent/JP2014523897A/ja
Publication of JP2014523897A5 publication Critical patent/JP2014523897A5/ja
Application granted granted Critical
Publication of JP5921679B2 publication Critical patent/JP5921679B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517952A 2011-07-07 2012-07-06 血漿カリクレインの阻害薬としてのベンジルアミン誘導体 Expired - Fee Related JP5921679B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161505305P 2011-07-07 2011-07-07
US61/505,305 2011-07-07
GB1111682.9A GB2494851A (en) 2011-07-07 2011-07-07 Plasma kallikrein inhibitors
GB1111682.9 2011-07-07
PCT/GB2012/051588 WO2013005045A1 (en) 2011-07-07 2012-07-06 Benzylamine derivatives as inhibitors of plasma kallikrein

Publications (3)

Publication Number Publication Date
JP2014523897A JP2014523897A (ja) 2014-09-18
JP2014523897A5 true JP2014523897A5 (enExample) 2015-08-20
JP5921679B2 JP5921679B2 (ja) 2016-05-24

Family

ID=44544412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517952A Expired - Fee Related JP5921679B2 (ja) 2011-07-07 2012-07-06 血漿カリクレインの阻害薬としてのベンジルアミン誘導体

Country Status (32)

Country Link
US (2) US9051249B2 (enExample)
EP (1) EP2729443B3 (enExample)
JP (1) JP5921679B2 (enExample)
KR (1) KR101999195B1 (enExample)
CN (1) CN103687846B (enExample)
AR (1) AR087102A1 (enExample)
AU (1) AU2012280064B2 (enExample)
BR (1) BR112014000240B1 (enExample)
CA (1) CA2841042C (enExample)
CL (1) CL2014000032A1 (enExample)
CO (1) CO6940413A2 (enExample)
CY (1) CY1117200T1 (enExample)
DK (1) DK2729443T6 (enExample)
ES (1) ES2560612T7 (enExample)
GB (1) GB2494851A (enExample)
HR (1) HRP20160101T4 (enExample)
HU (1) HUE027482T2 (enExample)
IL (1) IL230332A (enExample)
ME (1) ME02308B (enExample)
MX (1) MX343740B (enExample)
MY (1) MY185103A (enExample)
PH (1) PH12013502677A1 (enExample)
PL (1) PL2729443T6 (enExample)
PT (1) PT2729443E (enExample)
RS (1) RS54509B2 (enExample)
RU (1) RU2607045C2 (enExample)
SI (1) SI2729443T1 (enExample)
SM (1) SMT201600020B (enExample)
TW (1) TWI537238B (enExample)
UA (1) UA115427C2 (enExample)
WO (1) WO2013005045A1 (enExample)
ZA (1) ZA201400682B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040145T2 (hu) 2011-10-26 2019-02-28 Allergan Inc N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok
GB201212081D0 (en) * 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
ES2748434T3 (es) * 2014-01-10 2020-03-16 Univ Cornell Dipéptidos como inhibidores de inmunoproteasomas humanos
US11202817B2 (en) 2014-08-18 2021-12-21 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
EP4006012A1 (en) 2015-10-15 2022-06-01 Cornell University Proteasome inhibitors and uses thereof
ME03794B (me) 2016-05-31 2021-04-20 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609603D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201713660D0 (en) * 2017-08-25 2017-10-11 Kalvista Pharmaceuticals Ltd Pharmaceutical compositions
WO2019075252A1 (en) 2017-10-11 2019-04-18 Cornell University PEPTIDOMIMETIC INHIBITORS OF PROTEASOME
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
PL3716952T3 (pl) 2017-11-29 2022-05-02 Kalvista Pharmaceuticals Limited Postacie dawkowania zawierające inhibitor kalikreiny osoczowej
CN112135825A (zh) 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
CN111217670B (zh) * 2018-11-25 2021-04-09 中国科学院大连化学物理研究所 一种催化还原化合物中羰基为亚甲基的方法
CN113474318A (zh) * 2019-04-22 2021-10-01 南京明德新药研发有限公司 用作血浆激肽释放酶抑制剂的双环烷类化合物
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021032933A1 (en) * 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors
CN114728962B (zh) 2019-09-18 2025-09-19 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
JP7245397B2 (ja) 2020-03-04 2023-03-23 メッドシャイン ディスカバリー インコーポレイテッド 複素環化合物
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
TW202228686A (zh) 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療
WO2022084693A1 (en) 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Treatments of angioedema
JP7787890B2 (ja) 2020-11-19 2025-12-17 メルク・シャープ・アンド・ドーム・エルエルシー 血漿カリクレイン阻害剤
JP2024505596A (ja) 2021-02-09 2024-02-06 カルビスタ・ファーマシューティカルズ・リミテッド 遺伝性血管性浮腫の治療
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
US20250281397A1 (en) 2022-04-27 2025-09-11 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
EP4673437A1 (en) 2023-02-27 2026-01-07 Kalvista Pharmaceuticals Limited New solid form of a plasma kallikrein inhibitor
WO2025153806A1 (en) 2024-01-15 2025-07-24 Kalvista Pharmaceuticals Limited Methods for determining amidolytic activity
WO2025172692A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172693A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
WO1996031504A1 (en) * 1995-04-04 1996-10-10 Merck & Co., Inc. Thrombin inhibitors
JP4179878B2 (ja) * 2001-02-02 2008-11-12 中外製薬株式会社 ペプチド誘導体
GB0205527D0 (en) * 2002-03-08 2002-04-24 Ferring Bv Inhibitors
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
ES2365815T3 (es) * 2005-12-14 2011-10-11 Bristol-Myers Squibb Company Análogos de arilpropionamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor xia.
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) * 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
KR20100037600A (ko) * 2007-06-13 2010-04-09 브리스톨-마이어스 스큅 컴퍼니 응고 인자 억제제로서의 디펩티드 유사체
CN102026996B (zh) 2008-03-13 2015-01-07 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
US8609866B2 (en) 2009-12-18 2013-12-17 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2011094496A2 (en) * 2010-01-28 2011-08-04 The Medicines Company Trypsin-like serine protease inhibitors, and their preparation and use
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
ES2483802T3 (es) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasa
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
EP2697196A1 (en) 2011-04-13 2014-02-19 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein

Similar Documents

Publication Publication Date Title
RU2014104226A (ru) Бензиламиновые производные как ингибиторы калликреина плазмы
JP2014502979A5 (enExample)
CN101636154B (zh) Task-1和task-3离子通道抑制剂
JP6306609B2 (ja) 医薬組成物
RU2486181C2 (ru) Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
JP2010533160A5 (enExample)
JP2007039461A5 (enExample)
JP2011529037A5 (enExample)
JP2020530475A5 (enExample)
JP7159302B2 (ja) 線維性疾患の治療のための方法
RU2015142383A (ru) Новейшие антагонисты trpa1-рецепторов
RU2007119427A (ru) Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе
JP2013040215A (ja) 安定な乳化組成物
JP2003535844A5 (enExample)
JP2017509694A5 (enExample)
JP6957459B2 (ja) ニトロキシルドナーとしてのn−ヒドロキシルスルホンアミド誘導体
JP2011519832A5 (enExample)
JP2015131865A (ja) 抗癌用医薬
KR101422299B1 (ko) (2r)-2-〔(4-설포닐)아미노페닐〕프로판아마이드 및 이들 화합물을 함유하는 약학 조성물
JP2020530475A (ja) 医薬組成物
JP2011524362A5 (enExample)
WO2002045750A1 (en) Combination drugs
US20100029719A1 (en) Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors
JP2018520145A5 (enExample)
KR20100072008A (ko) 섬유증을 치료하기 위한 피페리디닐아미노-티에노[2,3-d]피리미딘 화합물